Luprolide Acetate (Lupron®, Eligard®)

BCommon name: Luprolide Acetate
Brand name: Lupron®, Eligard®
 

What is Luprolide Acetate?

Luprolide Acetate is a hormonal therapy medication that is used in the palliative treatment of advanced prostate cancer. It works by slowing or stopping the production of testosterone to stop or slow prostate cancer cells from growing and reproducing.
 

How is Luprolide Acetate administered?

Luprolide Acetate is administered by subcutaneous injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received luprolide acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast tenderness
  • Decreased libido
  • Diarrhea
  • Fatigue
  • Headaches
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Osteoporosis (weakened bones)
  • Weight gain
 

 Is Luprolide Acetate covered in my province or territory?*

Luprolide acetate (Eligard®) is covered by all provincial/territorial drug programs.

​Luprolide acetate (Lupron®​) is covered by provincial drug programs in:
  • Alberta​
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Quebec
  • Saskatchewan
​Luprolide acetate (Lupron®) is not covered by provincial drug programs in:
  • Northwest Territories
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Yukon

Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More


Click here for news archive